German biotech firm BioNTech (22UAy.DE), has agreed to acquire domestic peer CureVac, for about $1.25 billion worth of BioNTech shares, it said on Thursday, to boost its work on new mRNA-based cancer treatments.
Under the deal, which pairs two former rivals in the race to develop COVID-19 vaccines, CureVac shareholders stand to receive a premium of 55% over the three-month average share price, and leave them with a stake of about 4%-6% in BioNTech, the suitor said.
CureVac's Frankfurt-listed shares surged 27% to a five-month high, valuing the company at €1.04 billion ($1.2 billion), while BioNTech shares were down 2%.
The deal further underscores BioNTech's long-term pursuit of new cancer treatments as it aims to show that its success as Pfizer's COVID-19 vaccine partner, which left its balance sheet flush with billions of euros in cash, was not a fluke.
"With the acquisition, BioNTech aims to strengthen the research, development, manufacturing, and commercialization of investigational mRNA-based cancer immunotherapy," the company said.
CureVac opted to focus on oncology about a year ago when it agreed to sell its remaining influenza and COVID-19 vaccine development to alliance partner GSK.
It had previously cut jobs as it sought to move beyond its failure to develop an mRNA-based COVID vaccine during the pandemic.
GERMAN BIOTECH CHAMPION
The agreement is also set to end CureVac's years-long legal fight over alleged mRNA patent infringement by BioNTech and for a share of vaccine revenues, where CureVac has made little progress.
CureVac shares were worth as much as €120 in December 2020 on hopes it would develop a COVID vaccine, more than double their initial public offer value in August of that year. They are now trading at €4.65.
BioNTech won a major shot in the arm for its cancer drug activities last week when Bristol Myers Squibb agreed to pay up to $11.1 billion to jointly develop a next-generation cancer immunotherapy that could take on rival Merck & Co's best-selling drug Keytruda.
Each CureVac share will be exchanged for about $5.46 in BioNTech American depositary shares, or ADS, but subject to a so-called collar mechanism, BioNTech said.
If the 10-day volume-weighted average price of BioNTech ADS shortly before the closing of the offer exceeds $126.55, the exchange ratio would be 0.04318, and if the price is lower than $84.37, the exchange ratio would be 0.06476.
BioNTech said the deal was supported by SAP SE co-founder and football investor Dietmar Hopp, who holds a stake of about 37% in CureVac.
The German government, owner of about 13% in CureVac for its financial backing during the pandemic, said it welcomed in principle the creation of a "new German biotech champion", and that it would review the offer.
Start your day informed with AnewZ Morning Brief: here are the top news stories for the 12th of December, covering the latest developments you need to...
NATO's Secretary-General urged European leaders to step up defence efforts to prevent a war waged by Russia, that could be "on the scale of war our gr...
A powerful magnitude 6.7 earthquake has struck northern Japan, triggering tsunami warnings and forcing thousands of residents to flee to higher ground...
The resignation of Bulgaria's government on Thursday (11 December) puts an end to an increasingly unpopular coalition but is likely to usher in a peri...
Ukraine has presented the U.S. with a revised 20-point framework to end the war with Russia, President Volodymyr Zelenskyy said on Thursday, adding th...
The World Health Organization (WHO) has warned that Afghanistan is facing a worsening humanitarian and health crisis in 2025, with millions of returning refugees expected to stretch the country’s already fragile health system.
Qantas Airways has been fined A$90 million ($58.64 million) for illegally firing 1,800 ground staff during the COVID-19 pandemic and replacing them with contractors, the Federal Court of Australia said on Monday (August 18).
The COVID-19 pandemic exposed deep flaws in how the world prepares for and responds to global health threats. From overwhelmed hospitals to fragmented international coordination, the crisis revealed that preparedness goes beyond stockpiles. It requires trust, transparency, and global cooperation.
Honduras has brought back mask mandates as COVID-19 cases and a new variant surge nationwide.
In a dramatic Champions League clash at Baku’s Tofiq Bahramov Stadium, Qarabağ grabbed an early lead, but Ajax staged a thrilling comeback to win 4-2.
Iran is preparing to host a multilateral regional meeting next week in a bid to mediate between Afghanistan and Pakistan.
The United States issued new sanctions targeting Venezuela on Thursday, imposing curbs on three nephews of President Nicolas Maduro's wife, as well as six crude oil tankers and shipping companies linked to them, as Washington ramps up pressure on Caracas.
At least 19 people were killed and 16 injured as two buildings collapased in Morocco's Fes city according to the state news agency.
Iran's President Massoud Pezeshkian has begun a two day visit to Kazakhstan, with officials from both sides describing the trip as an opportunity to advance cooperation in trade, transport, industry, mining and cultural exchanges.
World Health Organization (WHO) Director-General Tedros Adhanom Ghebreyesus said on Thursday that he still hopes the U.S. administration will reconsider its decision to withdraw from the organisation next month, warning that its exit would be a loss for the world.
The United States has signed significant health cooperation agreements with Uganda and Lesotho, further strengthening bilateral relations and advancing global health initiatives, the U.S. State Department announced on Wednesday.
A viral claim circulating online that Denmark requires sperm donors to have an IQ of at least 85 is misleading. While one Danish sperm bank, Donor Network, does use an IQ threshold, there is no nationwide legal requirement for donors to meet a specific level of intelligence.
Chinese scientists have unveiled a new gene-editing therapy that they say could lead to a functional cure for HIV, making it one of the most promising developments in decades of global research.
The Democratic Republic of the Congo (DRC) has declared the end of a 16th Ebola outbreak, closing a two month emergency in Kasai Province that pushed national and international teams into an intensive response.
You can download the AnewZ application from Play Store and the App Store.
What is your opinion on this topic?
Leave the first comment